Cancer Advance is a terrific conference. The small setting and the friendly atmosphere result in meaningful interactions with decision makers
Boston, Massachusetts (PRWEB) March 24, 2016
Panels will discuss breakthrough designations, immunotherapy (including T cell therapy), precision medicine, combination therapy, innovative deal structures, biomarkers and more. Panelists include Jay Flatley (Illumina), Mike Kolodziej (Aetna), Liz Barrett (Pfizer), David Meek (Baxalta), Giulio Draetta (MD Anderson Cancer Center), Joe Eid (Merck), Andrew Schiermeier (EMD Serono), Bill McGivney (formerly of NCCN), Reid Huber (Incyte), Robert Bazemore (Epizyme), and Paul Lammers (Mirna), among others. Leading investors from Bain Capital, Longwood Fund, MPM Capital, SV Life Sciences Advisors, Sofinnova Ventures, and New Enterprise Associates will also be in attendance.
“Cancer Advance is a terrific conference. The small setting and the friendly atmosphere result in meaningful interactions with decision makers”, says Ferran Prat, Vice President of Strategic Industry Ventures at MD Anderson Cancer Center. “No other gathering is nearly as productive, and so thoroughly pleasant. Highly recommended.”
As Pablo Cagnoni, President and CEO of Tizona Therapeutics says, “Cancer Advance provides a highly interactive forum to discuss the latest trends, controversies and challenges that our industry faces, along with potential solutions. The off-the-record format allows for honest discourse among the industry's brightest thinkers. This is my third Cancer Advance conference and I come away from these meetings feeling energized about the scientific advances we are making on behalf of patients.”
The Oncology Innovation of the Year Award will be presented by George Demetri of the Dana Farber Cancer Institute at the close of the conference, April 5th at 5:20 pm.
Cancer Advance Boston is sponsored by H.C. Wainwright & Co., H3 Biomedicine, Applied BioMath, and BioPharma Executive Council.
To view the agenda and for more information, please visit: http://bbbiotechconference.com/conference-agenda.php?id=38
About The Boston Biotech Conferences (BBC)
The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of bio-pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information or to register, visit http://www.bbbiotechconference.com.